Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022

• Published in: International journal of clinical oncology 2024-05, Vol.29 (5), p.545-550
• Main Authors: Uchino, Keita, Tamura, Shingo, Kimura, Shoji, Shigeta, Keisuke, Kimura, Takahiro, Ozaki, Yukinori, Nishio, Hiroshi, Tsuchihashi, Kenji, Ichihara, Eiki, Endo, Makoto, Yano, Shingo, Maruyama, Dai, Yoshinami, Tetsuhiro, Susumu, Nobuyuki, Takekuma, Munetaka, Motohashi, Takashi, Ito, Mamoru, Baba, Eishi, Ochi, Nobuaki, Kubo, Toshio, Kamiyama, Yutaro, Nakao, Shinji, Tamura, Shinobu, Nishimoto, Hitomi, Kato, Yasuhisa, Sato, Atsushi, Takano, Toshimi, Miura, Yuji
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer Research; Chemotherapy; Cisplatin; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cisplatin - therapeutic use; Colony-stimulating factor; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Doxorubicin - therapeutic use; Febrile Neutropenia - chemically induced; Febrile Neutropenia - prevention & control; Granulocyte colony-stimulating factor; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - therapeutic use; Granulocytes; Hematuria; Humans; Leukocytes (granulocytic); Medicine; Medicine & Public Health; Meta-analysis; Methotrexate; Methotrexate - administration & dosage; Methotrexate - therapeutic use; Neutropenia; Oncology; Prophylaxis; Special Article; Surgical Oncology; Urologic Neoplasms - drug therapy; Urothelial cancer; Vinblastine; Vinblastine - administration & dosage; Vinblastine - adverse effects; Vinblastine - therapeutic use
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-024-02491-6

Granulocyte colony-stimulating factor (G-CSF) decreases the incidence, duration, and severity of febrile neutropenia (FN); however, dose reduction or withdrawal is often preferred in the management of adverse events in the treatment of urothelial cancer. It is also important to maintain therapeutic intensity in order to control disease progression and thereby relieve symptoms, such as hematuria, infection, bleeding, and pain, as well as to prolong the survival. In this clinical question, we compared treatment with primary prophylactic administration of G-CSF to maintain therapeutic intensity with conventional standard therapy without G-CSF and examined the benefits and risks as major outcomes. A detailed literature search for relevant studies was performed using PubMed, Ichu-shi Web, and Cochrane Library. Data were extracted and evaluated independently by two reviewers. A qualitative analysis of the pooled data was performed, and the risk ratios with corresponding confidence intervals were calculated and summarized in a meta-analysis. Seven studies were included in the qualitative analysis, two of which were reviewed in the meta-analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) therapy, and one randomized controlled study showed a reduction in the incidence of FN. Primary prophylactic administration of G-CSF may be beneficial, as shown in a randomized controlled study of dose-dense MVAC therapy. However, there are no studies on other regimens, and we made a “weak recommendation to perform” with an annotation of the relevant regimen (dose-dense MVAC).